Strategies for Enhancing Decentralized Clinical Trials

Clinical trial sponsors always look for ways to streamline the process to benefit patients and doctors. To that end, trial decentralization has become an indispensable tool. Instead of having patients go to a study site, more and more of the trials will be conducted at patients’ locations.

Due to the COVID-19 pandemic, there has been a dramatic rise in the number of Decentralized Clinical Trials being done remotely and in trial participants’ homes. Patient recruitment has been cut in half because of the high demand placed on the healthcare system due to COVID-19, rare diseases, and geographical barriers to travel.

The COVID-19 outbreak sparked the widespread adoption of decentralized trial design and management practices that had existed for some time but were seldom employed. Consumer and experimental virtualization have both been boosted by the epidemic. Since the worldwide epidemic persists, there is growing agreement that many initiatives will be permanent.

Enhancing the Adaptability of Clinical Trials

The pharmaceutical and biotech sectors are under increasing pressure to become more flexible, particularly in research and development. Organizations in the life sciences are increasingly taking a strategic and active interest in fields like personalized medicine, providing a significant incentive for change. A predicted 33 percent rise in cell therapy investment over the next five years is not surprising. The pharmaceutical industry invests in infrastructure development to turn cell therapy research into clinical practice.

Thus, it is a significant challenge for leaders within the life sciences sector to reimagine some research and development (R&D) domains to improve the speed and efficiency with which tailored therapies may be distributed to patients located in widely separated geographical regions.

Indicators of success will include the location and method of patient engagement and data collection. Healthcare delivery has already embraced telemedicine, mobile public health emergency methods, medical products, and wearable devices, but these solutions have not been adequately integrated into clinical trial participation. Decentralized clinical trials (DCTs), and remote monitoring models allow for more comprehensive, continuous data collection of patient experience in their natural environments or at home as technology improves.

The Food and Drug Administration’s (FDA) Rationale for Supporting Decentralization

Regulatory bodies have shown their approval of this kind of hybridized, real-time strategy. Such is the case with the U.S. Food and Drug Administration also known as the Drug Admin. Adoption of a new strategic framework to promote the use of real-world data to assist the development of medicines.

Clinical trials may benefit from decentralized human services studies. This is because they enable patients to obtain treatments from clinicians while decreasing managerial demands on sponsors and those carrying out the tests.

The New Challenges of Blockchain, Decentralization, and Traceability

Blockchain technologies are gaining traction in clinical trials to improve traceability and ensure compliance. The word “blockchain” has been used widely across sectors, with blockchain and digital health technologies being hailed as the panacea for the decentralization of corporate operations.

When it comes to patient data, for example, blockchain eliminates the issue of where it may be stored. It may be risky for patients who engage with many doctors or visit multiple private clinics to have their information shared across experimental sites. This problem is compounded by the fact that several EHR systems handle patient data, yet these systems are frequently incompatible, leading to a backlog of trial data. Instead of a centralized electronic health record, a blockchain-based, patient-centric decentralized approach might theoretically release the stifling information bottleneck.

R&D organizations have struggled with reporting and accountability. For example, according to a Forbes article, up to 90% of clinical studies listed had no findings as of 2017. The distributed ledger feature of blockchain, on the other hand, would ensure that only authorized medical practitioners and researchers had access to trial findings.

Decentralized Clinical Trials

Companies in the pharmaceutical and biotechnology industries would do well to take the initiative to learn about the dynamic digital environment that makes possible decentralized trials. As was previously indicated, decentralizing clinical trial transformation may provide substantial advantages, including enhanced patient-centeredness, more efficient resource management, and more reliable and accurate clinical research findings.

To gain an edge in the market, businesses are constantly debating whether to go the decentralized route or instead create hybrid protocols. To prepare for the potential effects of decentralization on their core businesses and research and development, life sciences companies must first identify these areas and elements.

Frequently Asked Questions (FAQs)

1. Who is Isaac Rodriguez-Chavez?

He oversees the medical side of things, the regulatory side of things, and the creation and execution of policies to ensure the smooth running of Decentralized Clinical Trials.

2. What are the various therapeutic areas?

• Cardiometabolic
• Ophthalmology
• Respiratory
• Immunology and dermatology